Inhalation challenge test using pigeon eggs for chronic hypersensitivity pneumonitis

2020 ◽  
Vol 50 (12) ◽  
pp. 1381-1390
Author(s):  
Ryo Okuda ◽  
Tamiko Takemura ◽  
Yu Mikami ◽  
Eri Hagiwara ◽  
Tae Iwasawa ◽  
...  
Author(s):  
Jens-Tore Granslo ◽  
Jorunn Kirkeleit ◽  
Stein Håkon Låstad Lygre ◽  
William Horsnell ◽  
Thomas Blix Grydeland ◽  
...  

2021 ◽  
Author(s):  
Ryo Okuda ◽  
Eri Hagiwara ◽  
Tomohisa Baba ◽  
Hideya Kitamura ◽  
Shigeru Komatsu ◽  
...  

Abstract Background: The inhalation challenge test is considered to be the “gold standard” for diagnosis of hypersensitivity pneumonitis (HP) and identifying the causative antigen in patients with fibrotic HP. However, the inhalation challenge test is not widely used. This study aimed to examine the value of the inhalation challenge test.Methods: This was a single-center, case control study. The patients with fibrotic HP were diagnosed pathologically by surgical lung biopsy or transbronchial lung cryobiopsy, and were assumed to be bird-related fibrotic HP if they had a history of obvious avian exposure. The patients with a histopathological diagnosis of fibrotic HP, no history of bird exposure and negative anti-bird antibodies were assumed to be non-bird-related fibrotic HP.Results: Based on pathological findings and history of avian exposure, 43 of 86 patients were diagnosed with bird-related fibrotic HP. In 43 patients with bird-related fibrotic HP, 15 (35%) were positive for anti-bird IgG antibody, and 36 (81%) were positive for the inhalation challenge test. Patients with both positive inhalation challenge test and anti-bird IgG antibodies had a 2.7% decline in annual FVC before the inhalation (p = 0.029). In patients with positive inhalation challenge test and the negative anti-bird IgG antibodies, the annual FVC decreased by 5.0% (p = 0.047). No significant FVC decline was observed in patients with negative inhalation challenge test and positive anti-bird IgG antibody, and those with both negative tests.Conclusions: The inhalation challenge test for bird-related fibrotic HP was more sensitive than anti-bird IgG antibodies. Furthermore, the inhalation challenge test was able to find a group of patients with FVC decline.


2021 ◽  
Vol 2021 (10) ◽  
Author(s):  
Mariko Ono ◽  
Yoko Nagatomo ◽  
Hayato Kinoshita ◽  
Yukihisa Takeda ◽  
Hiroyuki Nakamura ◽  
...  

ABSTRACT Acute respiratory illnesses that presented with diffuse ground-glass opacities (GGOs) on chest computed tomography (CT) scan suggest the diagnosis of coronavirus disease 2019 (COVID-19). However, many other diseases show similar CT findings, which often offer a difficult differential diagnosis. Here, we report a case of humidifier lung, a rare phenotype of hypersensitivity pneumonitis (HP), which mimicked COVID-19. A 71-year-old man was admitted because of dyspnea and diffuse GGOs found on chest CT scan. Although COVID-19 was initially suspected, his symptoms rapidly improved by the next day. A medical interview revealed that he had started using an ultrasonic humidifier 1 month ago. A high-resolution CT (HRCT) scan showed ill-defined centrilobular nodules and mosaic attenuation, which are typical of HP but atypical of COVID-19. The inhalation challenge test confirmed the diagnosis of humidifier lung. History-taking of humidifier use and a precise HRCT interpretation are helpful to differentiate it from COVID-19.


2020 ◽  
Vol 20 ◽  
Author(s):  
Hongwei Zhang ◽  
Steven Wang ◽  
Tao Huang

Aims: We would like to identify the biomarkers for chronic hypersensitivity pneumonitis (CHP) and facilitate the precise gene therapy of CHP. Background: Chronic hypersensitivity pneumonitis (CHP) is an interstitial lung disease caused by hypersensitive reactions to inhaled antigens. Clinically, the tasks of differentiating between CHP and other interstitial lungs diseases, especially idiopathic pulmonary fibrosis (IPF), were challenging. Objective: In this study, we analyzed the public available gene expression profile of 82 CHP patients, 103 IPF patients, and 103 control samples to identify the CHP biomarkers. Method: The CHP biomarkers were selected with advanced feature selection methods: Monte Carlo Feature Selection (MCFS) and Incremental Feature Selection (IFS). A Support Vector Machine (SVM) classifier was built. Then, we analyzed these CHP biomarkers through functional enrichment analysis and differential co-expression analysis. Result: There were 674 identified CHP biomarkers. The co-expression network of these biomarkers in CHP included more negative regulations and the network structure of CHP was quite different from the network of IPF and control. Conclusion: The SVM classifier may serve as an important clinical tool to address the challenging task of differentiating between CHP and IPF. Many of the biomarker genes on the differential co-expression network showed great promise in revealing the underlying mechanisms of CHP.


2012 ◽  
Vol 61 (1) ◽  
pp. 83-92 ◽  
Author(s):  
Tsukasa Okamoto ◽  
Yasunari Miyazaki ◽  
Ryutaro Shirahama ◽  
Meiyo Tamaoka ◽  
Naohiko Inase

2008 ◽  
Vol 22 (1) ◽  
pp. 38-46 ◽  
Author(s):  
Liisa K. Airaksinen ◽  
Timo O. Tuomi ◽  
Matti O. Tuppurainen ◽  
Antti I. Lauerma ◽  
Elina M. Toskala

Sign in / Sign up

Export Citation Format

Share Document